Tag: biosimilars

Insurance formulary changes in 2025 are pushing patients toward generics and biosimilars to cut costs. Learn how these shifts affect your copays, what to watch for, and how to protect your access to essential medications.

Biosimilars aren't exact copies of biologics - tiny manufacturing differences can trigger immune responses. Learn why some patients develop anti-drug antibodies and how regulators ensure safety despite these variations.

Patent expiry means cheaper generics-but only if you plan ahead. Learn what patients and healthcare systems must do now to avoid cost traps, side effects, and supply shortages as hundreds of drugs lose exclusivity.